Quest Partners LLC Akero Therapeutics, Inc. Call Options Transaction History
Quest Partners LLC
- $1.12 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AKRO
# of Institutions
172Shares Held
72.6MCall Options Held
178KPut Options Held
164K-
Janus Henderson Group PLC London, X06.88MShares$237 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$192 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$187 Million2.13% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$180 Million3.88% of portfolio
-
Wellington Management Group LLP Boston, MA5.11MShares$176 Million0.02% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.6B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...